Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen

ACE2/CHO-K1 Stable Cell Line

Produktgrößen
1 vial
£2797,00
14-523ACL-1VIAL
Über dieses Produkt
SKU:
14-523ACL
Weitere Details:
ACE2/CHO-K1 Stable Cell Line is a stably transfected CHO-K1 cell line which expresses human angiotensin-converting enzyme 2 (ACE2). ACE2 is a type I transmembrane metalloenzyme located on the outer surface of endothelial cells in the lung; arteries; heart; kidney and intestines. ACE2 cleaves the carboxyl-terminal amino acid phenylalanine from angiotensin II and hydrolyses it into the vasodilator angiotensin. ACE2 also serves as an entry receptor for some coronaviruses including HCoV-NL63; SARS-CoV and SARS-CoV-2 as the virus that causes COVID-19. Sequence data: hACE2 (accession number NP_068576) MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSS LASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQ NGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNE RLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYS RGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWT NLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLT DPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLL RNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTL PFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSN DYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPW TLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISL KSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFN FFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVS IWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASIDISKGENNPGFQNT DDVQT
Versandbedingungen:
Dry Ice
Lagerbedingungen:
Immediately upon receipt; store in liquid nitrogen.
Hersteller:
Abeomics
Typ:
Cells:Cell Lines
Fig-2: Binding of biotinylated SARS-Cov-2 Spike RBD protein to human ACE2 in the ACE2/CHO-K1 stable cell line. ACE2/CHO-K1 cells were probed with different amounts of biotinylated SARS-Cov-2 Spike RBD protein (Abeomics; Cat. No. 21-1005-B) and analyzed by flow cytometry through fluorescent-labeled Streptavidin detection.
Fig-3: Binding of biotinylated SARS-Cov-2 Spike RBD protein to human ACE2 in the ACE2/CHO-K1 stable cell line. ACE2/CHO-K1 cells were incubated with various concentrations of biotinylated SARS-Cov-2 Spike RBD protein (Abeomics; Cat. No. 21-1005-B) and analyzed through In-Cell ELISA. RBD binds to ACE2/CHO-K1 with an EC50 of 1.33 ug/ml.
Fig-4: Neutralization of binding between ACE2/CHO-K1 cells and SARS-Cov-2 Spike RBD protein by the Recombinant Anti-SARS-CoV-2 Spike RBD antibodies (CR3022: Abeomics; Cat. No. 10-2004 and ABMX-002: Abeomics; Cat. No. 10-2005). CHO-K1/ACE2 stable cells were incubated with various concentrations of RBD antibodies in the presence of biotinylated SARS-Cov-2 Spike RBD protein (Abeomics; Cat. No. 21-1005-B) and analyzed through In-Cell ELISA using HRP-Streptavidin for detection.
Fig-4: Neutralization of binding between ACE2/CHO-K1 cells and SARS-Cov-2 Spike RBD protein by the Recombinant Anti-SARS-CoV-2 Spike RBD antibodies (CR3022: Abeomics; Cat. No. 10-2004 and ABMX-002: Abeomics; Cat. No. 10-2005). CHO-K1/ACE2 stable cells were incubated with various concentrations of RBD antibodies in the presence of biotinylated SARS-Cov-2 Spike RBD protein (Abeomics; Cat. No. 21-1005-B) and analyzed through In-Cell ELISA using HRP-Streptavidin for detection.